Deals in brief
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Lilly to acquire Dermira for approximately $1.1bn
Eli Lilly and Company (Lilly) has signed a definitive agreement to acquire biopharmaceutical firm Dermira for approximately $1.1bn in cash.
As agreed, Lilly will acquire all outstanding shares of Dermira for $18.75 per share.
The acquisition will boost Lilly’s dermatology portfolio with the addition of Qbrexza (glycopyrronium), an anticholinergic to treat excessive underarm sweating (primary axillary hyperhidrosis) in patients nine years and above.
BioNTech acquires T cell therapy-focused Neon for $67m
Pfizer signs oncology agreement with STR-focused eFFECTOR
San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in the oncology field. The collaboration focuses on the development of small molecule inhibitors of eukaryotic initiation factor 4E (elF4E), a previously undruggable oncogenic target.
According to the terms of the agreement, eFFECTOR will receive a $15m upfront payment from Pfizer. It will also receive $492m in research and development (R&D) funding, as well as development and sales milestone payments.
NeuroBo Pharmaceuticals complete Gemphire merger
Almirall signs option agreement to acquire Bioniz Therapeutics
Spanish drugmaker Almirall has signed an option agreement to acquire Bioniz Therapeutics, a clinical-stage biopharmaceutical company in California.
The move aligns with Almirall’s strategy to support its research and development pipeline and develop a treatment for onco-dermatology and immuno-dermatology. If executed, the acquisition will provide Almirall with full global rights of BNZ-1, a novel multicytokine inhibitor currently under phase 1 / 2 development, designed to block the activity of IL-2, IL-9 and IL1-15 cytokines.
Altavant Sciences acquires Onspira Therapeutics
Altavant Sciences has signed a definitive agreement to acquire private drug development firm Onspira Therapeutics. Specific financial details of the transaction are yet to be divulged by either company. However, Onspira’s shareholders received an upfront payment, eligible for milestone payments and royalties on net sales.
The acquisition, already closed, provides Altavant with rights over OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) to treat bronchiolitis obliterans syndrome (BOS).